Media

Send Veracyte media related inquiries to media@veracyte.com.

Press Releases

Sharing Breaking News and Important Information

Veracyte Announces That New Study Suggests The Number Of Patients At Risk For Unnecessary Thyroid Surgery Is Likely On The Rise

Apr 17 2013

Veracyte Announces Appointment of Shelly D. Guyer as Chief Financial Officer

Apr 12 2013

Veracyte Announces Results of Study Assessing Use of BRAF Mutation Testing With Its Afirma^® Gene Expression Classifier

Mar 12 2013

Veracyte Announces UnitedHealthcare Coverage Policy For the Afirma^® Gene Expression Classifier

Mar 8 2013

New Article in PLOS Currents: Evidence on Genomic Tests Supports Use of Veracyte’s Afirma^® Gene Expression Classifier to Resolve Ambiguous Thyroid Nodule Biopsies

Feb 15 2013

Veracyte Announces That New Guidelines Include Molecular Testing for Indeterminate Thyroid Nodules To Reduce Unnecessary Surgeries

Jan 7 2013

Veracyte Announces Publication of Analytical Validity Study for its Afirma^® Gene Expression Classifier

The study adds to the growing body of published data supporting the company’s genomic test and underscores the rigorous standards we set for our test’s performance

Oct 22 2012

Veracyte Receives New York State License for Afirma^® Gene Expression Classifier

Veracyte and Genzyme Also Announce that Memorial Sloan-Kettering Cancer Center is Among the State’s First Institutions to Offer Genomic Test to Patients with Inconclusive Thyroid Nodule Results

Aug 29 2012

New Study Suggests That Use of Veracyte’s Afirma^® Gene Expression Classifier Helps to Significantly Reduce Surgeries in Patients with Ambiguous Thyroid Nodule Cytology Results

Jul 17 2012

Veracyte Announces Study Results Published Online in New England Journal of Medicine Which Suggest that Its Afirma^® Gene Expression Classifier Can Reduce Unnecessary Thyroid Surgeries

Findings Also Presented at ENDO 2012: The 94th Annual Meeting & Expo

Jun 25 2012

Genzyme and Veracyte Announce Expanded U.S. Availability of the Afirma^® Thyroid FNA Analysis for Improved Thyroid Nodule Diagnosis

Apr 16 2012

Richard T. Kloos, MD, Joins Veracyte as Senior Medical Director

Apr 5 2012

Genzyme and Veracyte Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients

Jan 20 2012

Veracyte Announces Medicare Coverage for Its Afirma^® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis

Jan 9 2012

New Data Suggest Veracyte’s Afirma^® Gene Expression Classifier Cost-Effectively Resolves Inconclusive Thyroid Nodule FNA Biopsy Results

Sep 1 2011

New Data Suggest Veracyte's Molecular Test Improves Accuracy of Thyroid Nodule Diagnosis Using Fine Needle Aspirate (FNA) Samples

Sep 15 2010

Veracyte Completes $28 Million Series B Round – One Step Closer to Commercializing First Molecular Diagnostic Product

Jun 9 2010